Factors explaining the gender disparity in lipid-lowering treatment goal attainment rate in Chinese patients with statin therapy
- PMID: 22642757
- PMCID: PMC3697899
- DOI: 10.1186/1476-511X-11-59
Factors explaining the gender disparity in lipid-lowering treatment goal attainment rate in Chinese patients with statin therapy
Abstract
Background: The lipid-lowering treatment goal attainment rate is lower for women than for men among Chinese patients, but the reasons for this disparity have not been fully explored yet.
Objectives: To elucidate the potential factors and the significance of their contributions towards the observed discrepancy in lipid-lowering treatment goal attainment rates between Chinese women and men.
Methods: We used data from 1808 patients from 21 tertiary and 6 secondary hospitals in China who received and maintained statin therapy treatment for at least 2 months. Lipid-lowering treatment goal attainment was defined as low-density lipoprotein cholesterol (LDL- C) reaching the treatment targets recommended by the Chinese Guidelines on Prevention and Control of Dyslipidemia in Adults. Logistic Regression was used to explore possible factors associated with gender disparity in goal attainment rates, and to what extent each factor contributes.
Results: A total of 674 women and 1134 men were enrolled in the study. Women had a significantly lower LDL-C goal attainment rate than that of men (46.0% vs 53.8%, P = 0.002), particularly in high and very high CVD risk groups. Among high and very high risk patients, approximately 35%, 7%, 5%, and 5% of gender disparity in LDL-C goal attainment rate was attributable to the gender difference in baseline LDL-C level, cardiovascular co-morbidities and associated risk factors, socioeconomic status, and the dosage of statin treatment, respectively. Approximately 50% of the gender disparity remained unexplained by these factors.
Conclusions: Although nearly half of the gender disparity in lipid-lowering treatment goal attainment rate can be explained by the gender differences in baseline lipid level, socioeconomic status, cardiovascular co-morbidities and associated risk factors, and the dosage of statin in high and very high CVD risk patients, the other half of the gender disparity remains unexplained and requires further study to fully understand what other factors are at play.
Figures
Similar articles
-
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.Vasc Health Risk Manag. 2013;9:719-27. doi: 10.2147/VHRM.S49840. Epub 2013 Nov 15. Vasc Health Risk Manag. 2013. PMID: 24265554 Free PMC article.
-
Obesity, ultrasound indexes of fat depots and lipid goal attainment in patients with high and very high cardiovascular risk: A novel approach towards better risk reduction.Nutr Metab Cardiovasc Dis. 2016 Feb;26(2):123-33. doi: 10.1016/j.numecd.2015.10.012. Epub 2015 Nov 26. Nutr Metab Cardiovasc Dis. 2016. PMID: 26830392
-
Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.J Cardiovasc Pharmacol Ther. 2020 Jul;25(4):307-315. doi: 10.1177/1074248419899298. Epub 2020 Jan 10. J Cardiovasc Pharmacol Ther. 2020. PMID: 31918567
-
Pitavastatin: novel effects on lipid parameters.Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Atheroscler Suppl. 2011. PMID: 22152282 Review.
-
Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom.Vasc Health Risk Manag. 2021 May 21;17:227-237. doi: 10.2147/VHRM.S269879. eCollection 2021. Vasc Health Risk Manag. 2021. PMID: 34054297 Free PMC article. Review.
Cited by
-
Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study.Lipids Health Dis. 2018 Feb 5;17(1):25. doi: 10.1186/s12944-018-0667-y. Lipids Health Dis. 2018. PMID: 29402296 Free PMC article.
-
Gender Disparities in Lipid Goal Attainment among Type 2 Diabetes Outpatients with Coronary Heart Disease: Results from the CCMR-3B Study.Sci Rep. 2017 Oct 4;7(1):12648. doi: 10.1038/s41598-017-13066-z. Sci Rep. 2017. PMID: 28978912 Free PMC article.
-
Sex-Specific Influence of the SCARB1 Rs5888 SNP on the Serum Lipid Response to Atorvastatin in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.Pharmgenomics Pers Med. 2020 Oct 29;13:553-561. doi: 10.2147/PGPM.S273346. eCollection 2020. Pharmgenomics Pers Med. 2020. PMID: 33154658 Free PMC article.
-
Sex difference in the incidence of stroke and its corresponding influence factors: results from a follow-up 8.4 years of rural China hypertensive prospective cohort study.Lipids Health Dis. 2019 Mar 25;18(1):72. doi: 10.1186/s12944-019-1010-y. Lipids Health Dis. 2019. PMID: 30909919 Free PMC article.
-
The Gut Microbiota-Produced Indole-3-Propionic Acid Confers the Antihyperlipidemic Effect of Mulberry-Derived 1-Deoxynojirimycin.mSystems. 2020 Oct 6;5(5):e00313-20. doi: 10.1128/mSystems.00313-20. mSystems. 2020. PMID: 33024047 Free PMC article.
References
-
- Randomised trial of cholesterol lowering. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–1389. - PubMed
-
- de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R. et al.Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–1316. doi: 10.1001/jama.292.11.1307. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical